GLP1R and type 2 diabetes mellitus: The clinical successes of the incretin trials utilizing GLP-1 receptor agonists (GLP-1ras) and GIP receptor agonists (GIPras) have been nothing short of “astonishing” in weight reduction [12,13], and in glucoregulation in type 2 diabetes (T2D) [14] and prediabetes [15].